Cochrane · systematic review · CD006622
Aripiprazole versus placebo for schizophrenia
Belgamwar, RB, El‐Sayeh, HGG · Cochrane Database of Systematic Reviews · 2011 · Cochrane Library
SchizophreniaAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
4
current version
GRADE rated
4
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 4 · 100%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Comparison
Population: people with schizophrenia or like psychosis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Poor compliance with study protocol | RR 0.72 [0.53, 0.97] | 8 studies · 2275 participants | Low |
Relapse | RR 0.66 [0.57, 0.75] | 2 studies · 573 participants | Low |
Weight gain (equal or greater then 7% of baseline) | RR 2.33 [1.17, 4.66] | 3 studies · 615 participants | Low |
Concomitant medication (Anxiolytic ‐ Lorazepam) | OR 0.96 | 2 studies · 787 participants | Low |